Subcellular localization of a thromboxane A2/prostaglandin H2 receptor antagonist binding site in human platelets. 1988

D L Saussy, and D E Mais, and D A Baron, and S H Pepkowitz, and P V Halushka
Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston 29425.

The subcellular localization of a binding site for the competitive thromboxane A2/prostaglandin H2 (TXA2/PGH2) antagonist, 9,11-dimethylmethano-11,12-methano-16-(3-iodo-4- hydroxyphenyl)-13,14-dihydro-13-aza-15 alpha beta-omega-tetranor TXA2 ([125I]-PTA-OH), was determined. Subcellular fractions of platelets were prepared by glycerol lysis or nitrogen cavitation, and were characterized by the use of enzymatic markers specific for plasma membranes, endoplasmic reticulum (dense tubular system), mitochondria, granules, and cytosolic constituents. The Kd and density of binding sites in the subcellular fractions were determined by Scatchard analysis of equilibrium binding data. The Kd and Bmax for [125I]-PTA-OH determined in the lysates were 49 +/- 11 nM and 4.1 +/- 1.7 pmol/mg protein respectively (N = 6). The Kd values were not significantly different in any of the fractions assayed. The binding sites were coenriched (4.5 +/- 0.66 fold) with the enzymatic markers for plasma membranes (3.7 +/- 0.5 fold) and dense tubular system (2.4 +/- 0.4 fold). The binding sites were not coenriched with markers for cytoplasmic constituents, mitochondria, or granules. The ability of the TXA2/PGH2 mimetic U46619 to compete with [125I]-PTA-OH for the binding site was also determined for the various subcellular fractions. The IC50 for U46619 was 5.4 +/- 1.2 microM in the lysate, and was not significantly different in the subcellular fractions. These data suggest that the binding site is the TXA2/PGH2 receptor described previously. These data are consistent with the notion that the putative TXA2/PGH2 receptor is localized in the plasma membranes and/or the dense tubular system.

UI MeSH Term Description Entries
D011449 Prostaglandin Endoperoxides Precursors in the biosynthesis of prostaglandins and thromboxanes from arachidonic acid. They are physiologically active compounds, having effect on vascular and airway smooth muscles, platelet aggregation, etc. Endoperoxides, Prostaglandin
D011450 Prostaglandin Endoperoxides, Synthetic Synthetic compounds that are analogs of the naturally occurring prostaglandin endoperoxides and that mimic their pharmacologic and physiologic activities. They are usually more stable than the naturally occurring compounds. Prostaglandin Endoperoxide Analogs,Prostaglandin Endoperoxide Analogues,Synthetic Prostaglandin Endoperoxides,Analogues, Prostaglandin Endoperoxide,Endoperoxide Analogues, Prostaglandin,Endoperoxides, Synthetic Prostaglandin
D011463 Prostaglandins H A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. The most frequently encountered member of this group is the prostaglandin H2.
D011982 Receptors, Prostaglandin Cell surface receptors that bind prostaglandins with high affinity and trigger intracellular changes which influence the behavior of cells. Prostaglandin receptor subtypes have been tentatively named according to their relative affinities for the endogenous prostaglandins. They include those which prefer prostaglandin D2 (DP receptors), prostaglandin E2 (EP1, EP2, and EP3 receptors), prostaglandin F2-alpha (FP receptors), and prostacyclin (IP receptors). Prostaglandin Receptors,Prostaglandin Receptor,Receptor, Prostaglandin,Receptors, Prostaglandins,Prostaglandins Receptors
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013928 Thromboxane A2 An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS). Rabbit Aorta Contracting Substance,A2, Thromboxane
D017482 Receptors, Thromboxane Cell surface proteins that bind THROMBOXANES with high affinity and trigger intracellular changes influencing the behavior of cells. Some thromboxane receptors act via the inositol phosphate and diacylglycerol second messenger systems. TP Receptors,Thromboxane Receptors,Receptors, Thromboxanes,TP Receptor,Thromboxane Receptor,Receptor, TP,Receptor, Thromboxane,Receptors, TP,Thromboxanes Receptors

Related Publications

D L Saussy, and D E Mais, and D A Baron, and S H Pepkowitz, and P V Halushka
October 1986, Biochemical and biophysical research communications,
D L Saussy, and D E Mais, and D A Baron, and S H Pepkowitz, and P V Halushka
November 1985, Biochemical and biophysical research communications,
D L Saussy, and D E Mais, and D A Baron, and S H Pepkowitz, and P V Halushka
November 1986, European journal of pharmacology,
D L Saussy, and D E Mais, and D A Baron, and S H Pepkowitz, and P V Halushka
July 1991, The Journal of biological chemistry,
D L Saussy, and D E Mais, and D A Baron, and S H Pepkowitz, and P V Halushka
May 1987, British journal of pharmacology,
D L Saussy, and D E Mais, and D A Baron, and S H Pepkowitz, and P V Halushka
December 1989, The Journal of clinical investigation,
D L Saussy, and D E Mais, and D A Baron, and S H Pepkowitz, and P V Halushka
January 1985, Advances in prostaglandin, thromboxane, and leukotriene research,
D L Saussy, and D E Mais, and D A Baron, and S H Pepkowitz, and P V Halushka
March 1994, The Journal of pharmacology and experimental therapeutics,
D L Saussy, and D E Mais, and D A Baron, and S H Pepkowitz, and P V Halushka
October 1990, Biochemical pharmacology,
D L Saussy, and D E Mais, and D A Baron, and S H Pepkowitz, and P V Halushka
October 1989, The Journal of biological chemistry,
Copied contents to your clipboard!